TY - JOUR T1 - Prediction of venous thromboembolism using clinical and serum biomarker data from a military cohort of trauma patients JF - BMJ Military Health JO - BMJ Mil Health SP - 402 LP - 407 DO - 10.1136/bmjmilitary-2019-001393 VL - 167 IS - 6 AU - Matthew Bradley AU - A Shi AU - V Khatri AU - S Schobel AU - E Silvius AU - A Kirk AU - T Buchman AU - J Oh AU - E Elster Y1 - 2021/12/01 UR - http://militaryhealth.bmj.com/content/167/6/402.abstract N2 - Introduction Venous thromboembolism (VTE) is a frequent complication of trauma associated with high mortality and morbidity. Clinicians lack appropriate tools for stratifying trauma patients for VTE, thus have yet to be able to predict when to intervene. We aimed to compare random forest (RF) and logistic regression (LR) predictive modelling for VTE using (1) clinical measures alone, (2) serum biomarkers alone and (3) clinical measures plus serum biomarkers.Methods Data were collected from 73 military casualties with at least one extremity wound and prospectively enrolled in an observational study between 2007 and 2012. Clinical and serum cytokine data were collected. Modelling was performed with RF and LR based on the presence or absence of deep vein thrombosis (DVT) and/or pulmonary embolism (PE). For comparison, LR was also performed on the final variables from the RF model. Sensitivity/specificity and area under the curve (AUC) were reported.Results Of the 73 patients (median Injury Severity Score=16), nine (12.3%) developed VTE, four (5.5%) with DVT, four (5.5%) with PE, and one (1.4%) with both DVT and PE. In all sets of predictive models, RF outperformed LR. The best RF model generated with clinical and serum biomarkers included five variables (interleukin-15, monokine induced by gamma, vascular endothelial growth factor, total blood products at resuscitation and presence of soft tissue injury) and had an AUC of 0.946, sensitivity of 0.992 and specificity of 0.838.Conclusions VTE may be predicted by clinical and molecular biomarkers in trauma patients. This will allow the development of clinical decision support tools which can help inform the management of high-risk patients for VTE.Data are available upon reasonable request from the corresponding author. ER -